BioSpace reported on May 14 that the biopharma job market saw year-over-year improvement in the first four months of 2026, with job postings increasing despite ongoing layoffs across the industry.
The trend is significant for professionals and companies in biopharma, as hiring gains may offset some impacts from workforce reductions. The data shows a complex employment landscape where growth in opportunities coincides with persistent layoffs.
April marked the third consecutive month of year-over-year increases in average job postings on BioSpace. While April's 4% rise was lower than February's 5% and March's 7%, it still indicated positive momentum. However, competition for these positions remains strong due to continued layoffs. From January to April this year, about 40 companies laid off or planned to lay off approximately 7,428 employees—nearly matching last year's total of 7,316 affected workers from nearly twice as many companies during the same period.
In April alone, nine biopharmas announced or projected cuts—a decrease from twenty-one a year prior—while affected employee numbers dropped by 40%. Earlier months also saw notable declines except for February when Viatris announced a multiyear restructuring that could impact up to 3,000 jobs globally based on recent filings. Layoffs continued into May; Takeda plans to eliminate around 4,500 roles this fiscal year while BioNTech intends to close facilities affecting about 1,860 jobs by late-2027. Combined May cuts have already surpassed those reported in May last year.
Geographically, Massachusetts and New Jersey led U.S. states for open biopharma positions posted on BioSpace in April—with both exceeding one thousand live jobs—but only Massachusetts and New York recorded month-over-month increases. Indiana is expected to see more activity following Eli Lilly’s announcement of a $4.5 billion investment into new manufacturing sites there aimed at creating high-quality jobs.
Recent positive developments include several initial public offerings such as Kailera Therapeutics’ record $625 million raise and Bayer’s acquisition of Perfuse Therapeutics for $300 million upfront—the company’s first pharma acquisition since 2021—potentially boosting future hiring trends.
